Search
  • ryanjamesjessup

BioMolecular Imaging | Frequently Asked Questions

Updated: Apr 28

BioMolecular Imaging understands that molecular and anatomic imaging continues to be an ever increasing and essential component of clinical drug trials.


We can help you answer the following questions:

  1. What is the potential value of imaging to my company’s development programs?

  2. What imaging technologies are best suited to my needs?

  3. How do I develop my imaging technology or probe internally or through outsourcing?

  4. How do I identify the best qualified academic sites or CROs for my projects?

  5. When is the best time to introduce imaging into my development plans?

  6. Do I need to develop a new imaging technology or are there established ones I can adopt?

  7. How do I optimize quality, accuracy, timeliness and standardization in my trial design and its execution?

  8. How can I maximally increase my company’s valuation by using imaging in order to leverage existing assets?

Early stage trials examine target accessibility and drug pharmacokinetics, while later phase studies employ imaging as an early indicator of response or as an efficacy endpoint.


But most, the Founder and Owner of our Company, Dr. J. James Frost, understands how new molecular probes from early phase studies become the future diagnostic agents that guide patient stratification for therapy and monitor patient response.


The truly staggering cost of drug development dictates that efficient practices must be employed at every development step. Therefore, the use of quantifiable and objective imaging endpoints can form the basis of the needed process efficiencies, accelerating development and decreasing costs.


First, de-risking late phase studies by using imaging to gain certainty that a drug candidate has target bioavailability and the required pharmacokinetics is sound science and solid business practice.


Early knowledge of failure also has great value in rechanneling resources to bring new candidates forward.


Second, the use of imaging as an early predictor of therapeutic response in late stage clinical trials is another strategy to accelerate outcomes and reduce costs.


A third example is, the use of imaging for study entry criteria to achieve uniform subject populations, thereby achieving tighter outcomes and earlier statistical endpoints.


While imaging is an extremely powerful technology, it is a complex process itself. Most companies, however, don’t have the internal imaging expertise required to plan and carry out imaging studies.


BioMolecular Imaging can help you to develop your company’s internal strategy and navigate imaging process steps to achieve tactical certainty, interface effectively with the necessary external partners, and maximize power of inference using best practice image analytics.


About BioMolecular Imaging


BioMolecular Imaging (BMI Consultants) is a molecular imaging and clinical trial consultancy owned and operated by Dr. J. James Frost M.D./Ph.D out of Baltimore Maryland. BMI has been involved with clinical, therapeutic & diagnostic imaging focused on Oncology, Brain, Biomarkers, Cardiology and Central Image Interpretations for over 20 years.


To learn more about BioMolecular Imaging, please visit https://www.BioMolecularImaging.com or connect with:


SoundCloud - https://soundcloud.com/BioMolecular-Imaging

Facebook - https://www.facebook.com/BMIConsultants

Twitter - https://twitter.com/BMIConsultants

LinkedIn - https://www.linkedin.com/company/BioMolecular-Imaging

YouTube - https://www.youtube.com/channel/UCkdv6cOQ8HunygNTtU66s2w


Copyright © 2022 BioMolecular Imaging


BioMolecular Imaging is a registered trademark of BioMolecular Imaging D.B.A. BMI Consultants

34 views0 comments

Recent Posts

See All

Diagnostic imaging is a core competency of BioMolecular Imaging - and is the approach of imaging the human body to analyze and form medical intervention, especially when viewing the function of organs

Imaging in therapeutic trials is the key process in expanding the understanding, methodology and metrics which are required to make determinations in drug targeting and efficacy. This spans most all i

A very active area of current investigation and commercialization is molecular and functional biomarker development. These biomarkers can serve as surrogate endpoints for therapeutic efficacy and are